More than 60% of @entity1 on chronic haemodialysis (HD) have a serum @entity1391 level above 5.5 mg/dl (1.75 mmol/l), which recently has been recommended as an appropriate target in @entity1 with @entity454 ( @entity454 ). Preventing hyperphosphataemia and elevated Ca x P product not only ameliorates the progression of @entity3528 and @entity79 , but also appears to reduce cardio-vascular morbidity and mortality from @entity729 . Dietary @entity1391 restriction and the administration of @entity5715 and @entity460 salts have been the principal means of @entity1391 control over the last decade. Unfortunately, the protean disturbances of toxic @entity5715 accumulation in the body virtually eliminated @entity5715 from clinical practice. @entity460 -based therapy, although well tolerated, results in frequent hypercalcaemia when administered concurrently with @entity560 analogues, despite a decrease in the concentration of dialysate @entity460 . Sevelamer (Renagel((R))) has been a novel, non-absorbable @entity460 - and @entity5715 -free synthetic polymer. In initial studies, sevelamer reduced serum @entity1391 , Ca x P product and @entity461 ( @entity461 ) in a manner comparable with @entity18279 therapy. However, the effect on @entity461 levels may prove to be inconsistent. It seems somewhat less effective in binding @entity1391 than @entity5715 , although no direct comparisons have been made. In a recent study, it attenuated the progression of @entity729 in HD @entity1 . It also binds @entity3645 , resulting in substantially lower low-density lipo-protein @entity165 levels. The major obstacle to its current use is a substantial increase in the cost associated with sevelamer therapy.

Hyperphosphataemia and treatment with sevelamer in haemodialysis XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity18279 :: ('MESH:C120662', 'Chemical') :: ['calcium acetate'] @entity3528 :: ('MESH:D006962', 'Disease') :: ['secondary hyperparathyroidism'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone disease'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D'] @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol'] @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium', 'Calcium'] @entity729 :: ('MESH:D061205', 'Disease') :: ['vascular calcifications', 'vascular calcification'] @entity3645 :: ('MESH:D001647', 'Chemical') :: ['bile acids'] @entity461 :: ('5741', 'Gene') :: ['PTH', 'parathyroid hormone'] @entity5715 :: ('CHEBI:28984', 'Chemical') :: ['aluminium'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease', 'ESRD']
@entity1 :: (9606,Species) :: ['patients']
